GET DAILY SIGNALSInMode Ltd. (INMD): Can Shares Climb +24% to the $16.50 Analyst Target?
Key Takeaways
- The central target of $16.50 is the arithmetic mean of four verified analyst price targets, which range from $15 to $19.
- With the stock trading near $13.30, reaching $16.50 implies upside of roughly 24% — a substantial move, not a modest one.
- Consensus is firmly "Hold": three of the four analysts rate the stock Hold, while Barclays is the lone Buy at $19.
- Supporting factors include roughly $500 million in net cash, a low valuation, recurring consumables revenue, and ongoing buybacks.
- The biggest risks are flat revenue, margin compression, patent litigation, and an unresolved, contentious M&A and governance situation.
- For more context on this ticker, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
Analyst Price Targets and Consensus View
The $16.50 central target comes from four current analyst estimates: Canaccord Genuity at $15 (Hold, October 2026), Jefferies at $15 (Hold, April 2026), Robert W. Baird at $17 (Hold, July 2026), and Barclays at $19 (Buy, May 2026). The arithmetic mean works out exactly to $16.50, with the range spanning $15 to $19. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The spread is fairly narrow, but the ratings lean cautious overall. Barclays sees value in the depressed valuation and cash position, while the Holds highlight uncertain demand for aesthetic equipment and limited visibility on near-term profits. BTIG and Needham cover the name without numeric targets. This average is independently calculated, not an official consensus figure.
Current Market Position and Path Toward the Target
The stock recently traded around $13.30, below the roughly $15 level seen during active takeover bids. Reaching $16.50 would mean a gain of about 24%, which stands out as a meaningful move for a business with largely flat to declining revenue.
Any path higher would likely depend on earnings stabilization, margin improvement, resolution of the takeover overhang, and valuation re-rating from the current P/E near 11. Modest revenue forecasts — essentially flat for 2026 and low-single-digit growth in 2027 — point to multiple expansion and strategic clarity as the main drivers rather than rapid top-line growth.
What Could Support a Move Toward the Target
InMode’s balance sheet remains a clear strength, with roughly $500 million in cash and minimal debt. Most of its roughly $790 million market capitalization is backed by cash and short-term investments. The company stays profitable, generates free cash flow, and continues share repurchases. Growth in recurring consumables and service revenue from the installed base provides some stability beyond equipment sales.
Prior takeover activity offers a reference point: Steel Partners bid $16.75 per share in cash, and a CEO-led group proposed $16.20 before that offer lapsed in September 2026. Those levels, above the current price, show that informed buyers have seen value near the central target.
What Could Prevent the Target From Being Reached
Demand for aesthetic capital equipment stays soft amid higher financing costs and competition from injectables and GLP-1 weight-loss drugs. Revenue declined from about $492 million in 2023 to roughly $370 million in 2025, and 2026 guidance of $365–$375 million points to another essentially flat year. Gross margin has eased to about 75% from 78%, with repeated guidance cuts since early 2024.
An ongoing governance dispute, including a hostile board campaign by Steel Partners and conflict allegations around the CEO, adds execution and strategic uncertainty. Patent litigation around Morpheus8 products, including ITC proceedings, and geopolitical risks tied to Israeli manufacturing create additional overhang.
Technical Levels and Market Structure
Over the past year the stock has ranged between roughly $12.72 and $16.74. The $12.72 area marks major support at the 52-week low, while $16.74–$16.75 forms a resistance cluster that aligns with both the 52-week high and Steel Partners’ offer price. The $16.50 target sits just below that resistance zone.
Time Horizon and What Investors Should Monitor
Analyst targets generally reflect a roughly 12-month horizon, though specifics vary. I’m watching quarterly earnings and guidance closely, especially signs of revenue stabilization and margin support. Other items include takeover and board developments, Morpheus8 patent litigation updates, interest-rate changes affecting customer financing, and any analyst target revisions.
Exploring AI Daily Buy/Sell Signals
For traders who prefer a systematic approach, I use AI Daily Buy/Sell Signals to monitor market shifts and generate Buy, Sell, or Hold signals based on technical behavior and AI-driven analysis. The platform helps me discover opportunities and spot changing trends more efficiently than manual review alone. Those looking to complement fundamental research with data-driven timing can explore how it evaluates names like InMode.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INMD's RSI Indicator ascends from oversold territory
The RSI Indicator for INMD moved out of oversold territory on November 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 29 of the 35 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where INMD advanced for three days, in 164 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
INMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INMD as a result. In 73 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for INMD turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 28 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.
The 50-day moving average for INMD moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for INMD entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.219) is normal, around the industry mean (4.142). P/E Ratio (10.750) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.834) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.452) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 63 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. INMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of minimally-invasive aesthetic medical products
Industry MedicalNursingServices
Advertisement